PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
New to PCSK9 Forum
ESC Congress 2021, 27-30 August, Virtual Meeting

What made the lipid news at this year’s virtual congress? PCSK9 Forum covered the latest late breaking news and clinical sessions, as well as insights from key poster presentations.


HUYGENS
Steve Nicholls Treatment with evolocumab favourably modified plaque phenotype, suggesting stabilization of vulnerable plaque after acute coronary syndrome.

Read the report »

Prof Steve Nicholls (Monash University, Melbourne, Australia) discusses HUYGENS.

Watch the video »

PCSK9-NATURE
Brian Ference Earlier reduction in LDL cholesterol provides greater lifetime benefit, according to results of this naturally randomized ‘target’ trial, presented by Prof Brian Ference (University of Cambridge, Cambridge, UK).

Read the report »

More from ORION-9, -10 and -11
Prof Derick Raal Inclisiran was similarly effective in patients with polyvascular disease or cerebrovascular disease, according to the latest subgroup analyses.

Read the report »

Prof Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) discusses the clinical implications from these ORION analyses.

Watch the video »

Round-up of the poster sessions
Statin intolerance, real-world treatment patterns in familial hypercholesterolaemia, and more.

Read the report »

PCSK9 Slides
TG Forum

Like us
For the latest updates, PCSK9 news and analysis.
Follow us
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Novartis Sanofi
Copyright PCSK9 Forum 2021. Please click here to unsubscribe from future mailings.. View on the web